A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Effect of BMS-986165 on the Blood Levels of Metformin
- Status
- COMPLETED
- Phase
- PHASE1
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
- Status
- COMPLETED
- Phase
- PHASE1
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
- Status
- COMPLETED
- Phase
- PHASE2
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- Status
- TERMINATED
- Phase
- PHASE1